529 related articles for article (PubMed ID: 33738705)
21. Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia.
Wang J; Tomlinson B; Lazarus HM
Curr Treat Options Oncol; 2023 Jul; 24(7):770-801. PubMed ID: 37195589
[TBL] [Abstract][Full Text] [Related]
22. FLT3 inhibitors in AML: are we there yet?
Sudhindra A; Smith CC
Curr Hematol Malig Rep; 2014 Jun; 9(2):174-85. PubMed ID: 24682858
[TBL] [Abstract][Full Text] [Related]
23. FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia.
Grunwald MR; Levis MJ
Semin Hematol; 2015 Jul; 52(3):193-9. PubMed ID: 26111466
[TBL] [Abstract][Full Text] [Related]
24. Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia.
Chi SG; Minami Y
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216478
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic implications of menin inhibition in acute leukemias.
Issa GC; Ravandi F; DiNardo CD; Jabbour E; Kantarjian HM; Andreeff M
Leukemia; 2021 Sep; 35(9):2482-2495. PubMed ID: 34131281
[TBL] [Abstract][Full Text] [Related]
26. Advances in the pharmacological management of acute myeloid leukemia in adults.
Numan Y; Abaza Y; Altman JK; Platanias LC
Expert Opin Pharmacother; 2022 Sep; 23(13):1535-1543. PubMed ID: 35938317
[TBL] [Abstract][Full Text] [Related]
27. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
Stansfield LC; Pollyea DA
Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
[TBL] [Abstract][Full Text] [Related]
28. From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia.
Yilmaz M; Daver N
Drugs; 2019 Jul; 79(11):1177-1186. PubMed ID: 31222627
[TBL] [Abstract][Full Text] [Related]
29. [Acute myeloid leukemia].
Döhner K; Paschka P; Döhner H
Internist (Berl); 2015 Apr; 56(4):354-63. PubMed ID: 25787321
[TBL] [Abstract][Full Text] [Related]
30. Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapy.
Nakamura F; Arai H; Nannya Y; Ichikawa M; Furuichi S; Nagasawa F; Takahashi W; Handa T; Nakamura Y; Tanaka H; Nakamura Y; Sasaki K; Miyano S; Ogawa S; Mitani K
Int J Hematol; 2021 Jun; 113(6):936-940. PubMed ID: 33400143
[TBL] [Abstract][Full Text] [Related]
31. IDH Inhibitors in AML-Promise and Pitfalls.
McMurry H; Fletcher L; Traer E
Curr Hematol Malig Rep; 2021 Apr; 16(2):207-217. PubMed ID: 33939107
[TBL] [Abstract][Full Text] [Related]
32. Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a
Ballesta-López O; Solana-Altabella A; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P
Future Oncol; 2021 Jan; 17(2):215-227. PubMed ID: 32975130
[TBL] [Abstract][Full Text] [Related]
33. Acute myeloid leukemia transformed to a targetable disease.
Saleh K; Khalifeh-Saleh N; Kourie HR
Future Oncol; 2020 May; 16(14):961-972. PubMed ID: 32297538
[TBL] [Abstract][Full Text] [Related]
34. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
Garcia JS; Stone RM
Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394
[TBL] [Abstract][Full Text] [Related]
35. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
Yang F; Anekpuritanang T; Press RD
Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
[TBL] [Abstract][Full Text] [Related]
36. Protein Kinase Inhibitors as Therapeutic Drugs in AML: Advances and Challenges.
Ling Y; Zhang Z; Zhang H; Huang Z
Curr Pharm Des; 2017 Nov; 23(29):4303-4310. PubMed ID: 28671056
[TBL] [Abstract][Full Text] [Related]
37. [Novel therapies for acute myeloid leukemia based on genomic aberrations].
Umezawa Y; Kawamata N
Rinsho Ketsueki; 2019; 60(6):594-599. PubMed ID: 31281150
[TBL] [Abstract][Full Text] [Related]
38. Acute Myeloid Leukemia Mutations: Therapeutic Implications.
Papayannidis C; Sartor C; Marconi G; Fontana MC; Nanni J; Cristiano G; Parisi S; Paolini S; Curti A
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31163594
[TBL] [Abstract][Full Text] [Related]
39. Emerging small molecular inhibitors as targeted therapies for high-risk acute myeloid leukemias.
Sahasrabudhe KD; Albrethsen M; Mims AS
Expert Rev Hematol; 2023; 16(9):671-684. PubMed ID: 37405412
[TBL] [Abstract][Full Text] [Related]
40. Acute myeloid leukemia: advancing clinical trials and promising therapeutics.
Daver N; Cortes J; Kantarjian H; Ravandi F
Expert Rev Hematol; 2016 May; 9(5):433-45. PubMed ID: 26910051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]